Caissargues, May 12, 2022
|
In K€ |
2020-2021 |
2021-2022 |
Var |
Turnover 3 | 111,669 | 118,446 | +6.1% |
|
9 month turnover |
333,033 |
341 491 |
+2.5% |
The Bastide Group achieved a solid third quarter with revenue of €118.5 million, up +6.1%, accelerating compared to previous quarters.
This performance benefited in particular from the contribution of companies acquired less than a year ago for €10.9 million. Like-for-like
1
, the decline was -3.8%, due to the gradual return to normal in sales of personal equipment (PPE) in the “Home Support” activity after the very strong demand recorded during the health crisis. The more technically demanding activities (Respiratory, Nutrition-Perfusion-Stomatherapy) continue to grow and account for the majority of sales at more than 54%.
This quarterly acceleration brings 9-month revenue to €341.5 million, an increase of +2.5% since the start of the year (-3.3% on an organic basis).
Breakdown of 9-month turnover by business
Home support
: Over the first 9 months of the financial year, sales amounted to €155.6 million, down -11.8% (-13.8% on an organic basis). This change is explained solely by the contraction in PPE sales at the end of the health crisis (-81.6%). Excluding PPE, the division grew by +9.5%.
-
In communities
, the Group posted revenue of €70.5 million, down -16.3% (-16.5% on an organic basis). Excluding the impact of PPE sales, revenue grew by +11.9%, reflecting the good momentum and resilience of activity in this sector, including with private establishments. -
In stores/online
, revenue amounted to €85.1 million, down -7.8% (-11.3% on an organic basis). Excluding PPE, the change is +7.5%. The Group is continuing to develop its activity in stores and is accelerating its e-commerce development, in particular with the contribution of the company Distrimed acquired at the end of 2021.
“Breathing” activity
generated revenue of €98.3 million, up 18.2% (+10.6% organically). This dynamic performance is based on significant market share gains which largely offset the impact of the significant price reduction in France for the treatment of sleep apnea. The Group also recorded solid organic growth in Spain and England and also benefited from the first contribution of the Canadian company Medpro acquired in February 2022 in the amount of €1.5 million.
The “Nutrition-Perfusion-Stomatherapy” activity
posted revenue of €87.6 million, up +19.4%, of which +6.4% organically. All segments of this activity are growing organically, at a globally consistent level of between 5% and 8%. This positive trend confirms the Group’s market share gains in this area.
2021-2022 outlook confirmed
The Group is pursuing its roadmap and confirming its objective of annual revenue of at least €460 million with a current operating margin objective of at least 8.3%.
The demanding basis of comparison on the “Home care” activity linked to the increased activity generated during the health crisis will begin to fade, which should allow a gradual return to organic growth at Group level in the next quarters.
The Bastide Group also confirms its growth strategy based on the priority development of activities with the highest technicality and high recurrence, both in France and internationally. External growth opportunities continue to be actively studied with this in mind in order to strengthen the Group’s positions.
NEXT MEETING
: 2021-2022 annual revenue on Wednesday August 31 after market close
1
Organic growth calculated at constant exchange rates and at constant scope, restating 2020-2021 for the contribution of companies acquired less than 12 months ago
The resumption of quotation will take place on May 13, 2022 at the opening of the markets. Trading has been suspended today to preserve fairness of information for all investors.
About Bastide Medical Comfort Group
Created in 1977 by Guy Bastide, the Bastide Group is one of the main European players in home healthcare services. Present in 6 countries, Bastide develops a permanent quality approach and is committed to providing medical devices and associated services that best meet the needs of patients in key health areas: diabetes, nutrition, infusion, respiratory, stomatherapy and urology. . Bastide is listed on Euronext Paris (ISIN: FR0000035370, Reuters BATD.PA, – Bloomberg BLC: FP).
|
Bastide Group |
Finance News | |
|
Vincent Bastide/Olivier Jourdanney Phone +33 (0)4 66 38 68 08 www.bastide-groupe.fr |
Analysts-Investors Guillaume Le Floch Phone +33 (0)1 53 67 36 70 |
Press – Media Deborah Schwartz Phone +33 (0)1 53 67 36 35 |
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
yZiek8lolW7Fxp5yl51qZ5dsmmllk5TFmZeZyWiZl5jHmZxplmpkmsmVZnBlmm5v
– To check this key:
https://www.security-master-key.com.
Regulated information:
Quarterly financial information:
– Third quarter financial information
Full and original press release in PDF format:
https://www.actusnews.com/news/74599-ca-9-mois-2021-2022-vff2.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com